Cargando…

Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer

SIMPLE SUMMARY: Therapeutic antibodies are an integral part of treatment regimens for metastasized colorectal cancer. In KRAS wildtype tumors both bevacizumab and cetuximab are active. While bevacizumab has previously been shown to induce tumor hypoxia, we here report that EGFR inhibition by cetuxim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urban, Hans, Maurer, Gabriele D., Luger, Anna-Luisa, Lorenz, Nadja I., Sauer, Benedikt, Stroh, Christopher, Trojan, Jörg, Mittelbronn, Michel, Steinbach, Joachim P., Harter, Patrick N., Ronellenfitsch, Michael W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589936/ https://www.ncbi.nlm.nih.gov/pubmed/33092032 http://dx.doi.org/10.3390/cancers12103050

Ejemplares similares

The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
por: Foltyn, Martha, et al.
Publicado: (2019)

Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems
por: Luger, Anna-Luisa, et al.
Publicado: (2018)

Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death
por: Luger, Anna-Luisa, et al.
Publicado: (2020)

Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide
por: Lorenz, Nadja I., et al.
Publicado: (2021)

AMPK activation protects astrocytes from hypoxia-induced cell death
por: Barialai, Leli, et al.
Publicado: (2020)

Hypoxia Enhances the Antiglioma Cytotoxicity of B10, a Glycosylated Derivative of Betulinic Acid
por: Fischer, Sebastian, et al.
Publicado: (2014)

Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet
por: Voss, Martin, et al.
Publicado: (2018)

Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
por: Heinzen, Dennis, et al.
Publicado: (2019)

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2018)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

Serine-dependent redox homeostasis regulates glioblastoma cell survival
por: Engel, Anna L., et al.
Publicado: (2020)

Correction: Serine-dependent redox homeostasis regulates glioblastoma cell survival
por: Engel, Anna L., et al.
Publicado: (2021)

Gene Suppression of Transketolase-Like Protein 1 (TKTL1) Sensitizes Glioma Cells to Hypoxia and Ionizing Radiation
por: Heller, Sonja, et al.
Publicado: (2018)

Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors
por: Harter, Patrick N., et al.
Publicado: (2015)

Inhibition of mTOR signaling protects human glioma cells from hypoxia-induced cell death in an autophagy-independent manner
por: Divé, Iris, et al.
Publicado: (2022)

ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors
por: Bähr, Oliver, et al.
Publicado: (2017)

Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma
por: Thiepold, Anna-Luisa, et al.
Publicado: (2015)

Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas
por: Filipski, Katharina, et al.
Publicado: (2019)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy (†)
por: Sihver, Wiebke, et al.
Publicado: (2014)

Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide
por: Maurer, Gabriele D., et al.
Publicado: (2019)

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
por: Burger, Michael C., et al.
Publicado: (2017)

Expression Profile of Sonic Hedgehog Pathway Members in the Developing Human Fetal Brain
por: Tichy, Julia, et al.
Publicado: (2015)

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
por: Harter, Patrick N., et al.
Publicado: (2015)

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
por: Zeiner, Pia S., et al.
Publicado: (2019)

Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition
por: Urban, Hans, et al.
Publicado: (2020)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer
por: Marzi, L, et al.
Publicado: (2016)

Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors
por: Burger, Michael C., et al.
Publicado: (2016)

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern
por: Burger, Michael C., et al.
Publicado: (2017)

Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis
por: Luger, Anna-Luisa, et al.
Publicado: (2022)

Fermented Mistletoe Extract as a Multimodal Antitumoral Agent in Gliomas
por: Podlech, Oliver, et al.
Publicado: (2012)

Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model
por: Linder, Benedikt, et al.
Publicado: (2019)

EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma
por: Chaudhary, Ritu, et al.
Publicado: (2023)

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy
por: Steidl, Eike, et al.
Publicado: (2021)

Evolving role of cetuximab in the treatment of colorectal cancer
por: Schuch, Gunter, et al.
Publicado: (2009)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial
por: Voss, Martin, et al.
Publicado: (2021)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy
por: Maurer, Gabriele D, et al.
Publicado: (2011)

Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis—A Case Series of Three Patients
por: Koch, Agnes, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_75bsqg8g7rphafkl79eroprha1